TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway

uchar/E+ via Getty Images Increasingly unhealthy lifestyles are leading to a higher incidence of organ failure worldwide, and while organ transplantation is generally the preferred treatment for organ failure due to better outcomes and quality of life, organ supply is currently heavily constrained for a variety of reasons, leading to a waiting list that as of 2023, numbers over 100,000 patients in the U.S. alone. American medtech company TransMedics’s (NASDAQ:TMDX) disruptive FDA-approved medical device ...